Thank you very much, Sharon, and good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall first-half year financial results of 2026.

As always, the slides we are using today are shared in the investor section of our website at almirall.com. Please move to slide number 2.

Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risks, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today. Please move to slide number 3.

Presenting today are Carlos Gallardo, Chairman and Chief Executive Officer; Jon Garay, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer. Karl will start with the business highlights of the first half of 2026, followed by an update on biologics and the key growth drivers of our medical dermatology portfolio.

Karl will provide you with an update on the pipeline and R&D programs. Then, John will go through the financials before Carlos concludes the presentation and we open for questions.

I will hand over to Carlos Gallardo, our Chairman and CEO. Please move to slide number 5.

Thank you, Pablo, and good morning to everyone in the call. Almirall delivered a steady first half of 2026, broadly in line with our expectations and the trajectory set out at the beginning of the year, with performance expected to build progressively through the remainder of the year.

Net sales reached €603 million, with European dermatology once again acting as the primary growth engine. These results remain broadly consistent with recent trends and our full-year guidance.

This is why we are reiterating our full-year 2026 guidance, with growth expected to pick up towards the second half of the year. Turning to products, Ilumetri delivered steady double-digit growth around €125 million in the first half and remains firmly on track towards peak sales of over €300 million.

Ebgliss generated €84.5 million in the first half, close to doubling year on year. I will provide a bit more context on Ebgliss on the following slides.

Among other products, Wynzora continues to lead market share across key regions, while Klisyri delivered stable growth overall. We remain closely connected to the dermatology community, strengthening our partnerships with physicians through ongoing engagement at key platforms such as the 2026 American Academy, Skin Academy, and European Academy of Dermatology and Venereology's symposium.

On the innovation side, we continue to make progress. We have several proof-of-concept and Phase 2 programs advancing, most of which are first or potentially best in class.

The initiation of Phase 2 of our anti-21 monoclonal--IL-21, sorry, monoclonal antibody marks a key step in our hidradenitis suppurativa strategy. Combined with the IL-1RAP, now we have two differentiated assets targeting a disease with significant unmet need.

We also signed a strategic research collaboration and licensing agreement with TherTast Biotech, adding further depth to our innovation efforts. Karl will revisit our pipeline updates in greater detail.

Please move on to the next slide for an update on our biologics portfolio. Ilumetri net sales reached €125 million in the first half of the year, marking a steady 10.5% year-on-year increase.

Ilumetri continues to demonstrate a solid position in the psoriasis market, maintaining its share within the leading anti-IL-23 class, supported by real-world evidence such as the POSITIVE study data presented at the latest AAD and EADV congresses, which continue to highlight meaningful long-term benefits in patients' well-being and disease control. Moreover, we see additional opportunity to further strengthen the profile of Ilumetri.

For that reason, we plan to initiate the EVOLVE study in psoriasis to study the effect of the 200 mg dose in biologic-naive patients diagnosed for less than 2 years, further reinforcing Ilumetri's strong and growing long-term clinical evidence base. Karl will provide additional details on the EVOLVE study.

Performance remains consistent and we therefore continue to be firmly on track to deliver over €300 million in peak net sales, even as both the product and the class enter a more mature phase of the growth cycle. Please move to the next slide for Ebgliss highlights.

Since its approval in Germany in December 2023, Ebgliss has rapidly scaled to become our second largest product, underscoring one of the most successful atopic dermatotic--dermatitis launches in recent years. Second-quarter sales reached €43 million, up from around €26 million a year earlier, bringing first-half sales to approximately €85 million, close to double the level of the first half of 2025.

Despite the positive trajectory of the launch, the performance in the second quarter reflects two factors. First, we must recall that we had a strong performance in the first quarter, which set a higher base for comparison.

Secondly, we experienced some softness in accountancy like Germany, where a relatively modest pricing adjustment created a short-term uncertainty and may have resulted some sales shifting from June to July. In addition, we also experienced temporary minor volatility in certain other countries.

Overall, we have not changed our mid- and long-term view on Ebgliss, and we expect a strong clinical profile and continued healthy growth in the AD market to support Ebgliss sales. While we do not typically like to comment on individual product sales for the year, we are aware that where the consensus sits for Ebgliss and we remain comfortable around that figure.

On the clinical side, our collaboration with Lilly continues to support Ebgliss' positioning, with extensive lebrikizumab data including the ADlong 4-year results and the ADorable 1 pediatric data presented at recent scientific meetings. This week, the EMA admitted the submission of the pediatric indication of Ebgliss.

In June, the FDA approved the every-8-week maintenance dosing regimen for Ebgliss in the US. This approval further strengthens Ebgliss' profile in atopic dermatitis and supports its long-term competitiveness in the market.

We are also conducting the ADhOC 2 trial in Europe, which has the potential to support an extension of the dosing interval to every 12 weeks. I will now hand over to Karl to walk you through our pipeline developments in more detail.

Thank you, Carlos, and good morning to everyone on the call. On this slide, I would like to focus on the early- and mid-stage pipeline as a source of future value creation and upcoming clinical inflection points.

Today, we have four proof-of-concept or Phase 2 studies ongoing, with two additional studies planned to start towards the end of this year. During 2025, we advanced two important programs into Phase 2: our anti-IL-1RAP antibody in hidradenitis suppurativa and the IL-2 mutein Fc in alopecia areata.

In addition, our partner, Simcere, initiated a Phase 2 study of IL-2 mutein Fc in atopic dermatitis. We also recently started a proof-of-concept study for our anti-IL-21 antibody in hidradenitis suppurativa.

Looking ahead, we plan to initiate two further proof-of-concept studies: IL-2 mutein Fc in SLE with cutaneous manifestation, and the anti-IL-1RAP antibody in inflammatory skin disease. Taken together, this gives us six proof-of-concept or Phase 2 studies with data readouts expected over the next couple of years, beginning at the end of 2026.

These programs remain early, but they are anchored in well-defined biology and give us a diversified set of potential first- or best-in-class opportunities in area of high unmet need. Next slide.

While we advance the clinical pipeline, we're also building the next wave of innovation in dermatology. Our approach is to focus Almirall's internal capabilities on deep disease understanding and to partner selectively where external technology can provide the most appropriate modality for a novel therapeutic hypothesis.

A recent example is our strategic research collaboration with TherTast Biotech, a Spanish biotechnology company with mRNA and lipid nanoparticle discovery and development expertise. Together, we aim to discover novel treatments for rare dermatological diseases and recurrent cutaneous conditions.

The important point is that this is a partner-enabled model. We access differentiated technology, while Almirall retains global rights and leads future development and commercialization.

This allows us to broaden our innovation reach while maintaining strategic control over assets that fit our dermatology focus. Next slide.

This slide summarizes our lifecycle management activity for products already on the market. The objective is to support the long-term relevance of our key brands through label expansion, additional clinical evidence, and disciplined prioritization of investment.

For tirbanibulin, the regulatory process for the larger 100-square-centimeter treatment area is ongoing, and we now expect the European approval towards the end of this year. Together with our partners, Sun Pharma and Eli Lilly, we continue to advance label expansion opportunities and generate additional clinical data for Ilumetri and Ebgliss, respectively.

For lebrikizumab, we have filed with the EMA for pediatric label extension to include children from 6 months to 17 years of age and awaiting below 40 kg with moderate to severe atopic dermatitis, with approval expected around mid-2027. We are also running a Phase 3 of lebrikizumab in nummular eczema with readout expected in 2029.

Additional ongoing clinical studies are summarized in the appendix. Turning to tildrakizumab, the INSPIRE 1 and 2 studies showed benefit in psoriatic arthritis.

Both trials met the primary endpoint at week 24 and continued to show benefit through week 52. After evaluating the access dynamics and investment required, we have decided not to pursue commercialization of tildrakizumab in psoriatic arthritis in Europe.

We believe that further investment in generating additional data in psoriasis can generate more value for tildrakizumab, and we therefore plan to study tildrakizumab in psoriasis patients with short disease duration and high disease burden. Details are shown on the next slide.

EVOLVE-PsO is designed to explore the potential benefit of tildrakizumab 200 mg in biologic-naive adults with moderate to severe plaque psoriasis and short disease duration defined as less than 2 years. In addition, the study will evaluate the potential to maintain high levels of disease control using a dose spacing approach.

We plan to initiate the study around year end, with first readouts are expected in 2029. Strategically, EVOLVE-PsO is intended to support a more flexible and patient-centric treatment paradigm.

If successful, it could help reinforce the value proposition of tildrakizumab in psoriasis by maintaining outcomes while potentially reducing treatment burden. With that, I will hand over to John for the financial review.

Thank you, Karl, for the pipeline updates, and good morning, everyone. Net sales for the first half reached €603 million, a 7.5% growth year on year and a 10% growth in the last 12 months, which is in line with provided net sales guidance range.

Please note that the second quarter of 2026 included the recently announced divestment of Acticell, comprising of a €13 million upfront and an additional €1 million revenue recognition out of the remaining payments. As noted, the year is progressing positively, with increasing performance expected during the remaining part of the year, as indicated in February earnings call.

European dermatology keeps delivering solid double-digit growth, reinforcing Almirall's path towards leadership in medical dermatology. We will review the details in the coming slides.

EBITDA for the first half came in at €151 million, resulting in a ratio of 25% over net sales versus 21.7% prior year, representing an improvement by 330 basis points. Gross margin benefited from Acticell divestment and is expected to normalize in upcoming quarters amid ongoing pressure from higher royalty tiers associated with Ilumetri's net sales growth.

Regarding SG&A, investment reflects the timing of our promotional activities during the year, and there will be some pick-up in the coming quarters. On R&D expenses, our half-year phasing reflects the progress of our trials into Phase 2, with four already ongoing and another two set to start shortly.

We closed the first half with a net cash to EBITDA ratio of around 0.1, with strong cash generation in the first half of the year, leaving us with significant financial flexibility. Overall, these results lead us to reiterate our 2026 guidance.

Let's move to the details of our sales breakdown on the next slide. European dermatology continued to perform positively in the first 6 months, with double-digit year-on-year net sales growth.

We will go into more details on the next slide. In general medicine and OTC, European sales reflect the divestment of Acticell completed in the second quarter.

Excluding this portfolio move, the segment remained broadly stable, with lower sales in some legacy products largely offset by contributions from products such as Ebastel and Airtal. In the United States, performance declined year on year, reflecting continued pressure on the legacy portfolio, which we will discuss on the next slide.

In the rest of the world, overall sales grew strongly, driven by solid dermatology demand. Let me take you through the dermatology performance in more detail on the next slide.

Our European dermatology business continued to perform well in the first half. Ilumetri delivered robust double-digit growth versus prior year, reaching €125 million.

Ebgliss further increased its contribution to approximately €85 million in the first 6 months of the year. We remain focused on unlocking the full value of the franchise from both the commercial and the R&D side.

Wynzora continued to build market share across core European countries, and Klisyri demonstrated stable growth in Europe year on year. In the United States, overall performance declined, reflecting continued pressure on the legacy portfolio.

Dollar-euro FX evolution represented a negative impact of -6% in our performance year to date. Seysara and Klisyri improved their price volume dynamics in the second quarter while still declining, and Aczone remained impacted by generic competition.

In the rest of the world, dermatology sales were driven primarily by Finjuve demand in China. Overall, our dermatology franchise continues to show solid underlying performance.

Let's briefly review the remaining elements of the P&L in the next slide. Gross margin reached 64.6% in the first half, with the second quarter divestment offsetting royalty impact associated with Ilumetri's growth.

SG&A in the second quarter followed an incremental quarter-on-quarter trend, as previously announced. We expect that trend to continue in the remaining quarters of 2026, while supporting margin expansion on an annual basis.

R&D percentage of net sales was somewhat lower than our target of 12.5%. Our half-year phasing reflects the progress of our trials into Phase 2, with four already ongoing and another two set to start shortly.

A full-year ratio of approximately 12.5% remains a good proxy, subject to the normal quarterly variability. EBITDA margin reached 25% of net sales, a level aligned with our 2028 ambition, but approximately 2.5 years ahead of schedule.

While this performance benefited from the divestment of a minor non-derma product, portfolio optimization is an integral part of our ongoing business strategy and value creation. This milestone demonstrates the strong position we are building.

Financial expenses continue to reflect the valuation impact of the equity swap, in line with the share price evolution during the period. Our effective tax rate continues to normalize, and we continue delivering on this positive trend, driven by the strong increase in the group's overall profitability, which materially reduces the relative impact of our US business at consolidated level.

Please move to the next slide to take a look at the balance sheet. Our balance sheet remained stable throughout the first half of the year.

Intangible assets reflect Ebgliss-related R&D capitalization, the development milestone to Simcere for advancing IL-2 mutein fusion protein into Phase 2, and the access fee linked to the FuOta collaboration, broadly offset by higher amortization. Our net cash to EBITDA ratio stood at around 0.1, providing us with strong financial flexibility for licensing opportunities and selective bolt-on acquisitions.

During the quarter, Moody's upgraded our credit rating to Ba1, validating the strength of our balance sheet and financial performance. Let's now turn to the cash flow statement.

Company generated €17 million cash in the first 6 months of the year, compared to a dilution of -€54 million in the same period last year, representing an improvement by €71 million. Free cash flow raised to €33 million, compared to -€20 million in the first half of 2025.

Let's now go through the different components of our cash flow. Cash flow from operating activities raised to €132 million, representing more than two times improvement versus prior year, driven by working capital management alongside higher profitability levels.

Cash flow from investing activities reflects the 2025 Ilumetri sales milestone paid in the first quarter, the highest milestone expected this year, with the remaining investment-related payments for the year being marginal, and the total outflow within the usual limits in absence of new acquisitions. Cash flow from financing activities reflects the change in the bond interest payment schedule following the recent bond issuance and cancellation of the previous one, as well as the dividend paid in the period.

With that, thank you very much for your attention, and I hand it over to Carlos for his closing remarks.

Thank you, John. To summarize, the first half of 2026 confirms that the business remains solid and on track.

We know where the consensus sits today and we are comfortable with these figures. Turning to the key drivers: First, our biologics portfolio continues to give us real momentum in a dermatology market that keeps expanding, with Ebgliss scaling across Europe and Ilumetri still growing steadily as it moves through a more mature phase of growth.

In parallel, we continue to generate robust lifecycle management data that further supports the strong profile of our biologics. Second, our growing and exciting pipeline now spans immune-mediated skin diseases, rare dermatology, and non-melanoma skin cancer, with six proof-of-concept Phase 2 programs moving forward and most assets being with potential for best or first in class, providing a solid base for sustainable growth without concentration on any single asset.

Third, we remain disciplined but active on capital deployment, with a strong balance sheet supporting bolt-on M&A and early-stage licensing. We continue to work towards delivering on our mid- and long-term ambitions, supported by a well-positioned portfolio, a strong and targeted pipeline, and strategic positioning in the right dermatology indications.

This combination of pipeline depth, financial discipline, and execution gives us confidence as we continue to advance Almirall towards leadership in medical dermatology. With that, we conclude the presentation and turn to Pablo for the Q&A.

Thank you very much, Carlos. Sharon, back to you for the Q&A, please.

Morning, team. Yes, thank you for taking my questions.

I've just got a couple. The first one, you mentioned there's a Germany pricing adjustment from July.

It'd be good to know a bit of clarity about what effect that's having in to H2 and also how this fits into maybe the German drug pricing reform that's taking effect in '27 and how you think that will impact Ebgliss and Ilumetri, and maybe whether that's included in your '28 EBITDA margin target of 25%. Then, my second question, please, is you didn't reiterate your peak guidance for Ebgliss.

Is there a reason for this? Just a bit more clarity.

Thank you.

Thank you, Hen. Not sure about the second question.

You're asking us to confirm the peak sales estimate for Ebgliss?

Yes.

Yeah. Sure.

Thanks for the questions, Hen. The German pricing reform is certainly not good news for the industry in Europe.

However, there's still a number of clarifications, as there are deductions and bonifications that now need to be clarified by the German government between now and the end of the year. Once we have clarity on this reform, we will be able to provide further clarity on how we see this impacting the business.

In terms of the peak sales guidance for Ebgliss, yes, we remain very confident on the outlook that we have provided, and so we are happy, very happy to reiterate peak sales above €450 million.

Great. Thank you.

Hi there. Thank you for taking my questions.

Just two from me, please. Are you able to quantify the extent of the planned price decrease for Ebgliss in Germany in July, or from July?

Then, secondly, can you tell us about some early ordering patterns you're seeing in 3Q for Ebgliss and whether you're expecting a return to acceleration from 3Q, despite the typical slowdown during the summer season? Thank you.

Thank you, Shan, for the questions. If I understood well, that you're asking about the price decrease in Germany in Ebgliss this year, it will be from January 1st, 2027.

Is that the question or not?

No, your question, Shan, if I understood well, you are asking the price reduction for Ebgliss in July, right?

Yes, exactly.

Yes. It has been a low-single-digit one that it was agreed with the German government at the point of launch of the product.

It is minor, but it has had an impact on the phasing of orders between quarters. We expect an acceleration in the Q3.

This is the answer of your first question.

You want to take-- Thanks. Sorry, I misunderstood the question.

Thanks, John, for your help.

[laughter]

You want to take number two as well?

Yes. Your second question, Shan, was about order pattern in the second half of the year and return to accelerate.

Yes, we remain confident in the long-term profile of the product. We continue receiving very positive feedback from our key opinion leaders in the market, and we continue having long-term lifecycle management.

The market consensus for the product, Shan, at this point in time is in the range of €190 to €193 million, and we remain comfortable in this ballpark for this year. Just to reiterate that our focus remains firmly on the long-term opportunity, and as usual, we would encourage all the analysts to have a view on 12 months more than on quarter-on-quarter facing.

Hope this addresses the answer to your question, Shan.

Thank you.

Hello, good morning. Thank you for taking my questions.

Two, if I may. First one, regarding this year's guidance.

After the H1 EBITDA, how should we interpret the guidance of €270 to €290 million for the year? Are you now maybe more comfortable with the upper half of the range?

Secondly, regarding Ilumetri, we've seen some moderation of the growth in Ilumetri in Q2. Are you still expecting double-digit growth for this year, and what contribution are you seeing from the 200--200 mg presentation?

Thank you.

Juan, thank you very much for your questions. At this stage, we are confirming our full-year guidance.

Yes, we had a very nice EBITDA in the first half. Not only that, we have already reached the 25% EBITDA ambition that we had set for ourselves in the mid-term guidance that we set up, and we had set this target for 2028.

We are very happy to see that we have been able to accelerate our operational leverage agenda, so that's great news. At this time, we are happy to confirm the full-year guidance that we have provided.

Ilumetri, perhaps for the details, I'll pass it to John, but let me reiterate that we remain very, very confident with the performance of Ilumetri, both in terms of how the market is growing, IL-23 is firmly established as the winning class, and within this class, we are able to either to keep or to grow market share. The underlying dynamics remain extremely positive for Ilumetri.

John, do you want to add some more color in Ilumetri?

Just to complement, Juan, that if I remember well, the market consensus is in the ballpark of €260, €262 million, similar level as of February earnings call, and the company feels comfortable with that ballpark, although we do not provide guidance per product. On long term, the guidance for the product is to reach peak sales beyond €300 million, and we also reiterate we are comfortable with that peak sales.

More importantly, Karl has been sharing with us exciting aspects of Ilumetri lifecycle management and product, if it is okay, Juan, I would like to pass the word to Karl to complement our answer.

Thank you. Just to remind everyone, Ilumetri is the only anti-IL-23 with dose flexibility, and we're seeing, especially on the 200 mg, where we receive very positive feedback, especially in patients that are overweight or with a high disease burden, and that's why we now start the EVOLVE-PsO study to further explore this 200 mg option in patients with a short disease duration and a high disease burden, and we are confident that this adds to the already very solid clinical evidence on Ilumetri and will further drive the product.

Hello, good morning. Thank you for taking my questions.

Two, if I may. I'm sorry to insist on the German reform, but taking into consideration the accelerated operating leverage that you have been achieving, is there a scenario in your preliminary analysis in which you would not rate the 25% margins in 2028 that you've been targeting?

The second question, you've been guiding for an underlying EBITDA growth acceleration across 2026, and you've been delivering upon it. You mentioned that you're comfortable with current consensus, which implies a major slowdown in the second half of the year.

I wanted just to confirm both statements, if you still think that you should have some acceleration, or if there could be a slowdown, and just to provide more details regarding this. Thank you.

Thanks for your question, Guilherme. Yes, as I mentioned, we're very happy to see our acceleration on the operational leverage agenda that we have established for ourselves.

In addition, we've seen very good progress, and I would say, I would rate it as excellent progress in our pipeline, with the six POCs by end of '26, and that means that we'll have all the data readouts in the next 18 months. This, and you were asking about the scenarios, right?

This opens many scenarios depending on the data, depending on the readouts, and we will be, of course, first, solving with value maximization for shareholders in mind, and secondly, monitoring very closely what this means. Your question on EBITDA for the second half of this year, maybe, John, you want to take it?

Yes, thank you very much, Carlos. Thanks a lot, Guilherme, for your question.

When you are doing the comparison, first of all, any potential scenario we have had in the first half of the year, including the divestment of a minor derma product, Acticell, was already included in the scenarios we provided for our full-year guidance in both net sales and EBITDA: 9% to 12%, and EBITDA amount, €270 to €290 [million]. Having said that, in the second half of the year, we expect certain acceleration in our R&D investment as our trials progresses, and we expect certain pick-up in our SG&A investment following the phasing of our promotional activities.

If you remember what we have always said is that SG&A will be a component, a key component to the operational leverage that you already see in the P&L as of today, but the growth will be materially lower than the growth we are showing in net sales. In this scenario, in the second half of the year, of course, in order to continue accelerating in the same ratio, we should have a similar divestment to the one we have executed for Acticell.

From an operational point of view, excluding the divestment, we continue expecting EBITDA acceleration. This would be our ambition, and still we are in the ranges we have provided for the full-year guidance range for 2026.

Thank you.

Thank you. Good morning.

A couple of questions from my side. The first one, more on the competitive landscape in AD.

Today, we've heard Sanofi's discontinuing amlitelimab. I would like to know your opinion and maybe to summarize which ones do you think are going to be the main competitors going forward?

The second one for Karl would be how excited you are with the new anti-IL-21 candidate that is passing to Phase 2 for hidradenitis suppurativa? Maybe if you can elaborate on this candidate versus, for example, the anti-1--IL-1RAP?

Thank you.

Thank you, Jaime, for for the questions. The competitive landscape in AD, we've always said that the AD market is largely underpenetrated, only around probably less than 20% of patients that are eligible for this type of advanced treatments are treated with with modern medicines.

For us, the the new entrants, new mechanisms of actions coming into this market continue to expand the market, right? Having said so, we remain the community and and it remains firmly convinced the the that the anti-IL-13 remains the mainstay treatment for first-line in patients, right?

Overall, we believe that that that, anti-IL-13 will continue for the future to become the mainstay, and market progression and feedback of physicians, these patients, make us very very continue to deliver post very positive signals for us on this market. Karl, do you want to comment maybe on on amli and the IL-21?

Yes, I think, yes, we saw the news on amlitelimab this morning. These decisions are always based on benefit-risk, yeah, and we need now to analyze what this could mean on our bispecific antibody, where this is only one component.

The other component is an anti-IL-13 mechanism that, as Carlos said, is the key pathogenic driver in AD. Now coming to your second questions, we're very excited about the anti-IL-21 antibody.

HS is an indication with a very high unmet medical need, but is also a very complex disease, and that's why we have been searching for mechanism that can address multiple pathways. The anti-IL-1RAP addresses multiple pathway more towards to the innate immune system, the IL-1 alpha, beta, the IL-33, and the IL-36 alpha, beta, and gamma.

Both the anti-IL-1 beta independently, as well as an antibody against the IL-36 receptor, have shown benefits addressing different aspects of the pathophysiology. We believe this combination of those activities when inhibiting the anti-IL-1RAP has a chance for an increased efficacy.

IL-21 is a cytokine that is involved both in B- and T-cell biology, addressing more the adaptive immune system. Again, there is evidence that addressing T cells and addressing B cells has impact on the pathophysiology of HS.

Our hypothesis is again that by combining those activity, this may lead to an increased efficacy. We have just started a Phase 2, kind of proof-of-concept study, and expect the first results during next year.

Thank you very much.

Yes, thank you for taking my questions. Just regarding the investments, if I remember correctly, you said that we should expect around €70 million for the year.

Is that still a good target? Then, what can we expect for next year?

Then, if you could remind us what could be the potential target markets for hidradenitis suppurativa and alopecia areata, and talk a bit on the competition right now that you could have on those fields? Thank you.

Joaquín, thank you very much for the questions. John, do you want to take the first one on investments and then Karl the ones on HS and AA?

Yes, thanks a lot, Carlos, and thanks for your question, Joaquín. I understand you refer to investment CapEx.

Should this not be the case, please feel free to speak up, and we also cover ordinary CapEx. In terms of investment CapEx, yes, our guidance for the full year was €70 to €80 million in absence of new acquisitions.

Our year today basically reflects the payment of our 2025 Ilumetri sales milestone, that is the highest we are going to experience this year. Right now, Joaquín, we confirm that range, probably ending to the high, to €75 to €80 million.

It is what we will be finalizing in our investment CapEx. Happy to say that the results we are presenting today while we are discussing CapEx, they also show the strong cash generation the company has achieved in the first 6 months of the year, I am confident we have enough muscle and power to fund those CapEx and potential new licensing opportunities that may come up in the near future.

Hopefully, I have addressed your question. Otherwise, let me know.

Back to Carlos for the--

Then to Karl.

Yes. Thanks for the question.

As I mentioned, HS is an indication with a still very high unmet need, and experts we have talked to mention that the currently available treatments are still sub-optimally in addressing all the different aspects, specifically the efficacy. The high unmet need is also reflected in the interest and in the pipeline.

We believe we have two very differentiated assets that have, as I just mentioned, a chance for an increased efficacy by addressing not a single, but multiple pathomechanisms. When it comes to the potential commercial opportunities, Evaluate estimate the HS market to be in the range of $5.3 billion in 2030, and the second, the AA market, alopecia areata, is estimated to be in the range of about $1.4 billion US dollar, again from Evaluate Pharma 2030 estimates.

It shows that both are significant commercial opportunities.

Thank you very much, Sharon. If there are no further questions, ladies and gentlemen, this concludes our today's conference call.

Thank you for your participation. You may now disconnect.